Yabao Pharmaceutical Group's (SHA:600351) subsidiary, Suzhou Yabao Pharmaceutical Research and Development, will conduct phase II clinical trials on its SY-009 capsules after receiving approval from China's National Medical Products Administration, according to a Monday disclosure on the Shanghai Stock Shanghai.
The product, which is being tested as a type 2 diabetes drug, will now be tested as a treatment for functional constipation.
The pharmaceutical company spent 87.2 million yuan on the research and development of the drug.
Shares of the company jumped more than 5% in recent trade.
Price (RMB): ¥6.14, Change: ¥+0.30, Percent Change: +5.14%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.